Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vunakizumab in active psoriatic arthritis
NCT05055934Phase 2Completed
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Oct 2021
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vunakizumab in psoriatic arthritis (PsA), sponsored by Suzhou Suncadia Biopharmaceutical. Started Oct 2021; status: completed.
02
Drugs
vunakizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT05055934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05055934.